In contrast, the A-ring bends 90° relative to the steroid nucleus when the C5 hydrogen is β/cis oriented, as in the case of 5β-reduced androgens such as 5β-DHT (see structural conformations in Fig. 2). We have observed that the A-ring of the steroid nucleus is planar in the structure of Tes and in the α/trans configuration at C5 of reduced metabolites such as 5α-DHT. Nevertheless, the dramatic difference in vasorelaxing potency between Tes and its dihydro-metabolites deserves further consideration, based on their different structural conformations. However, to our knowledge, there is no information available on the plasma concentrations of 5β-DHT; consequently, further research is urgently needed to determine the range of normal plasma concentrations of 5β-DHT. Whereas the circulating plasma concentration of Tes in adult men ranges 11–36 nmol/l, its 5α-reduced metabolite (5α-DHT) is present in the plasma at levels of only about 10% that of Tes (1.0–2.9 nmol/l). As a nonaromatizable dihydro-androgen metabolite of Tes, 5α-DHT has been frequently used as a tool to verify that the aromatization of Tes to estrogen is not required for this androgen to produce vasorelaxation (3, 8, 10, 64, 73). The LAD was isolated and placed in either prostaglandin or potassium chloride (KCl), another contracting agent, and testosterone. This study tested the effect of endothelial denudation as well as washing the vessels with either Krebs–Henseleit bicarbonate (KHB), or N‐nitro‐l‐arginine methyl ester (l‐NAME). Deenadayalu et al18 performed a similar study using the left anterior descending (LAD) coronary arteries of swine hearts. Statistical significance was observed at both 1 and 10 μmol/L of testosterone, and there was no difference between the groups with and without endothelium.16 This suggests that testosterone has a direct smooth muscle–relaxing effect and does not require endothelium to induce vasodilation. After 7 minutes in prostaglandin, arteries were washed and exposed to testosterone or control solution. Effects of a therapy on blood vessels that have been subjected to endothelial denudation would suggest that the drug is working through an endothelium‐independent and NO‐mediated‐independent mechanism, such as directly on the tunica media (smooth muscle layer) of an artery. There is little information regarding the mechanism by which testosterone exerts its cardioprotective effect regarding ischemic injury; thus, more research is required. In males, the testes‐intact plus placebo group had a significantly higher neutrophil density than the testes‐intact male plus estrogen group for the first 2 days after MI, suggesting estrogen inhibited neutrophil infiltration. Testosterone was given at 208 μg/day for 60 days to achieve approximately normal male physiological levels. They suggested that the discrepancies in results are a result of differences in the way testosterone interacts with different parts of the vessel. Vessels dilated with adenosine showed significantly more dilation than with adenosine plus testosterone. Ceballos et al41 conceded that testosterone can induce relaxation of the aorta and coronary arteries, but they also believed that testosterone may facilitate vasoconstriction. When treated with 5‐HT, aortas from the testosterone group displayed statistically significantly higher contraction percentages than those from the control group. Of the patients in the TRT group, 35% (20 of 57) experienced an improvement of ≥ 1 NYHA class in their functional capacity compared to only 9.8% of patients in the placebo group (5 of 51). Although T was shown to significantly improve exercise capacity, none of the studies found a significant change in LVEF, although NYHA class was shown to improve in two of the studies. Toma et al. performed a meta-analysis of these studies and discovered that there was a net pooled improvement of 0.52 standard deviations in exercise capacity among those who received TRT. Testosterone replacement therapy has been shown to significantly improve exercise capacity without affecting left ventricular ejection fraction (LVEF). The authors also verified that the odds ratio for having hypogonadism was significantly higher in obese men, and there was a statistically significant negative correlation between total T level and BMI.15 Testosterone replacement therapy (TRT) has been shown to decrease fat mass. There was no difference between the relaxation percentages of vessels with and without an endothelium at different testosterone concentrations. Vessels of intact animals dilated when given either of the 3 testosterone treatments without flutamide were compared with baseline. Crews and Kahill20 compared the initial degree of maximum contraction of endothelial‐denuded, extracted LAD arterial segments of rats to the percentage of contraction of rat LAD segments that had been treated with testosterone. The relaxation percentage, which is the amount of relaxation induced by testosterone compared with the contraction induced by prostaglandin, was determined. This study suggests that DHT, a nonaromatizable form of testosterone that has a high affinity for the androgen receptor, only alters macrophage genes in males.39 This may be an important part of the testosterone–atherosclerosis relationship, which was overlooked in this study, as the aromatization of testosterone to estrogens has been shown to inhibit atherosclerosis in male mice.36 In this study, white blood cells were more likely to adhere to endothelial cells in the presence of testosterone compared with control. DHEA increased very‐low‐density lipoprotein (VLDL), intermediate‐density lipoprotein (IDL), and low‐density lipoprotein (LDL) levels compared with levels before initiation of the high‐cholesterol diet in tested rabbits. In a study by Jackson and Hutson, diabetes was chemically induced in rats of both sexes.27 Diabetic rats showed significantly higher blood glucose levels accompanied by statistically lower levels of luteinizing hormone (LH), follicle‐stimulating hormone (FSH), insulin, and testosterone than control rats. Testosterone and 5α‐dihydrotestosterone administration yielded increased coronary blood flow independent of dose in intact animals, suggesting that vessels were dilated. At testosterone concentrations between 10−5 and 10−4 mol/L, the vessels treated with KCl showed greater contraction than those contracted with prostaglandin, but the trend of reduced contraction with increased testosterone concentration was still seen, suggesting that testosterone may be a vasodilator.20 Pham et al tested dofetilide, an antiarrhythmic agent that also may have proarrhythmic properties, against varying levels of testosterone in ventricular myocytes.5 The concentration of testosterone was measured against 90% action potential duration (APD90) and percent incidence of early after depolarizations (EADs). Thus, despite numerous research efforts to date, the role of hypogonadism in the pathogenesis of CVD remains unclear, as does the cardiovascular risk profile of TRT. This raises the possibility that these reductions in HDL-c do not confer increased CVD risk at all and conceivably could reflect a protective effect.